These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36571287)

  • 1. The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS.
    Thet AK; Kelly PJ; Kasule SN; Shah AK; Chawala A; Latif A; Chilimuri SS; Zeana CB
    Clin Infect Dis; 2023 May; 76(9):1671-1673. PubMed ID: 36571287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe soft tissue infection: A complication of mpox in an individual with HIV coinfection requiring vaccinia intravenous immunoglobulin and intravenous tecovirimat.
    Mahtani AU; Seelam H; Padda I; Mahmoud M; D Cuomo J; Khalil BW; Haider M; Khalil A; Elemam A; Nfonoyim J
    J Med Virol; 2023 Jul; 95(7):e28917. PubMed ID: 37394761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
    Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
    Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging pharmacological strategies for treating and preventing mpox.
    Grosenbach DW; Russo AT; Blum ED; Hruby DE
    Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prolonged Case of Severe Mpox as an Opportunistic Infection in Advanced AIDS.
    Malka MS; Parkinson M; Zucker J; McLean JR; Pereira MR; Yin MT; Gunaratne SH
    Cureus; 2024 May; 16(5):e59947. PubMed ID: 38854169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
    Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
    Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult.
    Dammann F; Raja M; Camargo JF
    Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
    Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
    Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1.
    Chen WH; Axell-House DB
    J Med Virol; 2023 Sep; 95(9):e29078. PubMed ID: 37665172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.
    Shearer JD; Siemann L; Gerkovich M; House RV
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2634-41. PubMed ID: 15980330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
    De Clercq E; Jiang Y; Li G
    Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.
    Hopkins RJ; Kramer WG; Blackwelder WC; Ashtekar M; Hague L; Winker-La Roche SD; Berezuk G; Smith D; Leese PT
    Clin Infect Dis; 2004 Sep; 39(6):759-66. PubMed ID: 15472804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City.
    Garcia EA; Foote MMK; McPherson TD; Lash MK; Bosompem AN; Bouscaren A; Chan J; DiLorenzo MA; Feihel D; Fowler RC; Gandhi V; Jenny-Avital ER; Kopping EJ; Mazo D; McLean J; Mgbako O; Sayegh MN; Shaw RN; Su M; Meissner JS; Wang JC; Wen W; Winters JC; Zeana CB; Zucker J; Wong M
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae294. PubMed ID: 38868307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged Mpox Disease in People With Advanced HIV: Characterization of Mpox Skin Lesions.
    O'Shea J; Zucker J; Stampfer S; Cash-Goldwasser S; Minhaj FS; Dretler A; Cheeley J; Chaudhuri S; Gallitano SM; Gunaratne S; Parkinson M; Epling B; Morcock DR; Sereti I; Deleage C
    J Infect Dis; 2024 Mar; 229(Supplement_2):S243-S248. PubMed ID: 38019806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anorectal Manifestations of Treatment-Refractory Monkeypox Requiring Surgical Intervention.
    Cherfan P; Massaad E; Hui VW
    Am Surg; 2023 Dec; 89(12):6370-6373. PubMed ID: 37186888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
    Pinnetti C; Cimini E; Mazzotta V; Matusali G; Vergori A; Mondi A; Rueca M; Batzella S; Tartaglia E; Bettini A; Notari S; Rubino M; Tempestilli M; Pareo C; Falasca L; Del Nonno F; Scarabello A; Camici M; Gagliardini R; Girardi E; Vaia F; Maggi F; Agrati C; Antinori A
    Lancet Infect Dis; 2024 Feb; 24(2):e127-e135. PubMed ID: 37778364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for severe or refractory mpox virus infection in patients with advanced HIV.
    Pettit NN; Imam S; Sherer R; Hazra A
    Int J STD AIDS; 2023 May; 34(6):366-373. PubMed ID: 36708269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome.
    Viguier C; de Kermel T; Boumaza X; Benmedjahed NS; Izopet J; Pasquier C; Delobel P; Mansuy JM; Martin-Blondel G
    Int J Infect Dis; 2022 Dec; 125():135-137. PubMed ID: 36397606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.